Blondeaux, Eva
Lambertini, Matteo
Michelotti, Andrea
Conte, Benedetta
Benasso, Marco
Dellepiane, Chiara
Bighin, Claudia
Pastorino, Simona
Levaggi, Alessia
Alonzo, Alessia Dā
Poggio, Francesca
Buzzatti, Giulia
Molinelli, Chiara
Fregatti, Piero
Bertoglio, Sergio
Boccardo, Francesco
Del Mastro, Lucia
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (no grant number)
Article History
Received: 8 August 2019
Revised: 25 February 2020
Accepted: 12 March 2020
First Online: 31 March 2020
Ethics approval and consent to participate
: The study was firstly approved by Ethics Committee of the coordinator centre (Ospedale San Martino IST) and subsequently by Ethics Committee of every participant centre. Written informed consent was obtained from all patients before trial enrolment. The study was performed in accordance with the Declaration of Helsinki.
: Not applicable.
: Data and results are available at IRCCS Ospedale Policlinico San Martino, Genova, Italy.
: M.L. served as a consultant for Teva and received honoraria from Theramex outside the submitted work. A.M. served as a consultant for EISAI, Novartis, Astra Zeneca, Teva, Pfizer and Celgene and received travel accommodation expenses from Eisai, Celgene and Novartis outside the submitted work. M.B. received honoraria from Merck, MSD and Bristol Myers Squibb outside the submitted work. L.D.M. received honoraria from Roche, Pfizer, Ipsen, Eli Lilly, Eisai, Novartis, Takeda and Amgen, served as a consultant for Eli Lilly, Roche and MSD and received travel grant from Roche, Pfizer and Celgene outside the submitted work. The remaining authors declared no competing interests.
: This work was supported by Grants of the Associazione Italiana per la Ricerca sul Cancro (AIRC) [no grant number]. This research was supported by the Italian Ministry of Health 5āĆā1000 funds 2014 and 2015 to Lucia Del Mastro [no grant number].